Despite no significant correlation of increased HAS3 expression with reduced patient clinical outcome or with any clinicopathologic characteristic, a concordant increase of both TNF-α and HAS3 expression not only was associated with lymph node metastasis but also further reduced overall survival among late-stage oral cancer patients. Here, HAS3 is linked to lip and oral cavity carcinoma.